ADA: EMPA-REG Continues To Impress With More Data For Lilly/Boehringer's Jardiance

Eli Lilly & Co. and Boehringer Ingelheim GMBH have once again excited doctors with further analysis presented at the American Diabetes Association's meeting for Jardiance (empagliflozin) from the EMPA-REG cardiovascular outcomes study – this time showing benefits for kidney protection.